Prostate cancer has become a global health concern as it is one of the leading causes of
mortality in males. With the emerging drug resistance to conventional therapies, it is imperative to
unravel new molecular targets for disease prevention. Cytochrome P450 (P450s or CYPs) represents
a unique class of mixed-function oxidases which catalyses a wide array of biosynthetic and metabolic
functions including steroidogenesis and cholesterol metabolism. Several studies have reported the
overexpression of the genes encoding CYPs in prostate cancer cells and how they can be used as molecular
targets for drug discovery. But due to functional redundancy and overlapping expression of
CYPs in several other metabolic pathways there are several impediments in the clinical efficacy of
the novel drugs reported till now. Here we review the most crucial P450 enzymes which are involved
in prostate cancer and how they can be used as molecular targets for drug discovery along with the
clinical limitations of the currently existing CYP inhibitors.
Keywords: Androgenesis, antimetastatic, Cytochrome P450, prostate cancer, xenobiotic, cancer cells.
Rights & PermissionsPrintExport